VIVA BIOTECH(01873): The environmental impact assessment report of Lianhua Pharmaceutical has been approved.

VIVA BIOTECH (01873) announced that its wholly-owned subsidiary Zhejiang Langhua Pharmaceutical Co., Ltd. recently received a reply from the Taizhou Ecological Environment Bureau regarding the environmental impact assessment report for the company's proposed production of several peptide and other small molecule drug intermediates. The reply approved Langhua Pharmaceutical's plan to renovate three existing factory buildings in the Lihai Industrial Park of the Zhejiang Province Chemical Pharmaceutical Base, in order to produce advanced intermediates for peptides and other small molecule drugs in accordance with the terms and plans outlined in the environmental impact assessment report. Langhua Pharmaceutical intends to implement the production plan outlined in the environmental impact assessment report, and will manage the project in accordance with the requirements and regulations set forth in the reply, as well as relevant laws and regulations, aiming to start production as soon as feasible. The production plan is expected to promote business growth and increase production capacity and efficiency for the group, resulting in benefits for the company. The company hereby declares that it does not make any predictions or forecasts about the profitability of the production plan for the group.